CHM Cannabis
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/10/2018 3:21:00 PM - Followers: 7 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
CHM Cannabis
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#714   Oxford BioMedica to capture 25-30% of lentiviral vector marcusl2 12/10/18 03:21:00 PM
#713   (This is VERY interesting) marcusl2 12/10/18 03:20:33 PM
#712   AXOVANT ANNOUNCES FEEDBACK FROM FDA MEETING REGARDING AXO-LENTI-PD georgejjl 12/06/18 10:01:13 PM
#711   Oxford Biomedica PLC Axovant FDA meeting feedback marcusl2 12/06/18 04:07:44 PM
#710   I agree George, but along with a few marcusl2 12/02/18 02:11:02 PM
#709   Novartis could buyout Oxford BioMedica georgejjl 12/01/18 04:40:40 PM
#708   Oxford BioMedica notes the longer-term analyses from pivotal georgejjl 12/01/18 03:27:20 PM
#707   Possible ways forward for Car T 5T4 combinations ? marcusl2 11/25/18 04:59:39 AM
#706   “Any new therapy is going to start in marcusl2 11/25/18 04:12:25 AM
#705   Scott Gottlieb, M.D. marcusl2 11/25/18 04:11:37 AM
#704   Digital tech from Autolus and Oxford BioMedica to marcusl2 11/22/18 11:41:18 AM
#703   Looking good. marcusl2 11/22/18 04:50:58 AM
#702   W. Buffett marcusl2 11/21/18 06:07:53 AM
#701   https://twitter.com/EWhiteheadFdn/status/1064918865786884097 marcusl2 11/20/18 01:46:18 PM
#700   Discussion The results of a Phase I/II clinical trial georgejjl 11/18/18 12:24:02 PM
#699   https://twitter.com/mwl471/status/1063371272120348672 marcusl2 11/16/18 05:17:24 AM
#698   Oxford BioMedica marcusl2 11/14/18 10:01:26 AM
#697   Edison Report regarding Oxford BioMedica georgejjl 11/09/18 08:26:37 PM
#696   OXB-102 trial georgejjl 11/07/18 09:04:55 PM
#695   Yes I am very optimistic George. marcusl2 10/30/18 04:46:17 AM
#694   Sheila Roy is a true pioneer for ProSavin georgejjl 10/30/18 01:29:12 AM
#693   Oxford BioMedica notes that Axovant doses first patient georgejjl 10/30/18 01:10:40 AM
#692   “The millions of patients with Parkinson’s disease globally marcusl2 10/25/18 08:03:42 AM
#691   The London, United Kingdom-based company plans to raise marcusl2 10/25/18 08:02:33 AM
#690   BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- marcusl2 10/16/18 04:22:15 AM
#689   See page 13 georgejjl 10/15/18 10:09:34 PM
#688   Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced georgejjl 10/05/18 01:05:09 PM
#687   Orchard Therapeutics plans $172.5 million U.S. IPO georgejjl 10/05/18 08:33:15 AM
#686   Good news. Orchard should be quite a valuable marcusl2 10/05/18 05:38:52 AM
#685   CART-19 before Oxford Biomedica georgejjl 10/02/18 09:14:10 PM
#684   Last, but not least, RetinoStat has been developed georgejjl 09/19/18 08:17:55 PM
#683   Wet AMD marcusl2 09/18/18 04:02:53 AM
#682   All animals treated with 1×10^7 total T georgejjl 09/17/18 11:33:34 PM
#681   Long-term follow up of a phase 1/2 study georgejjl 09/17/18 11:21:08 PM
#680   Stuart, finances for Axo-Lenti-PD pretty spectacular. Firmly believe marcusl2 09/13/18 04:43:34 PM
#679   Fast forward to 1:01:57 to listen to our marcusl2 09/06/18 04:34:32 PM
#678   https://www.metro.news/cancer-kids-get-wonder-drug-on-nhs/1213179/ marcusl2 09/05/18 05:00:57 AM
#677   spec calls for 80 percent of those cells marcusl2 08/31/18 04:24:27 AM
#676   ...Kymriah has been predicted to generate billions of georgejjl 08/28/18 02:58:46 AM
#675   http://crweworld.com/article/news-provided-by-globenewswire/783750/novartis-rece marcusl2 08/27/18 06:21:43 AM
#674   If I can find these companies before mainstream marcusl2 08/23/18 04:26:59 PM
#673   Overlooked molecule might be key to how well marcusl2 08/21/18 03:44:28 PM
#672   Vasant Narasimhan, CEO, Novartis speaking about Kymriah; marcusl2 08/21/18 03:43:30 PM
#671   Cancer stem cells (also called cancer-initiating cells) are marcusl2 08/21/18 03:42:55 PM
#670   (AAV). These gene therapy vectors do not integrate marcusl2 08/21/18 06:15:40 AM
#669   Very interesting georgejjl 08/19/18 09:16:40 AM
#668   Hi George, I don`t really understand it however marcusl2 08/18/18 03:47:43 AM
#667   Very interesting patent georgejjl 08/17/18 07:27:48 PM
#666   Scientists Race To Improve 'Living Drugs' To Fight Cancer georgejjl 08/16/18 07:25:56 AM
#665   Notice of Interim Results marcusl2 08/15/18 03:21:22 AM
PostSubject